The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.

CompanyOverview\|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

It is evaluating multiple candidates in late-stage studies, including mRNA-1647 (cytomegalovirus [CMV] vaccine), mRNA-1010 (influenza vaccine) and mRNA-4157/V940 (individualized neoantigen therapy).

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $2.69. In the year-ago period, the company had reported ...

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase ...

Moderna has been utilizing its messenger-RNA technology on personalized cancer vaccines. Its mRNA-4157, in collaboration with Merck & Co. MRK and its blockbuster Keytruda, has proven to cut ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

One of the biotech’s most valued pipeline assets, Merck & Co.-partnered individualized neoantigen therapy mRNA-4157 (V940), uses AI to tailor treatment to each cancer patient. In 2023 ...